Developing GMP-Manufactured Cas9 Proteins for Therapeutic Applications

Register Free: https://www.biopharminternational.com/bp_w/gmp

Event Overview:

As CRISPR-based gene editing progresses from research to therapeutic applications, there is a growing need for high quality GMP-grade materials, including the Cas9 protein and supporting instruments. The risk of off-target events must also be evaluated and minimized.

This webcast will:

• Discuss the requirements for a GMP manufactured Cas9, including quality control and functional performance
• Walk through a full primary T-cell editing workflow along with evaluating the performance of the edited cells
• Review the potential causes of undesired off-target events and how to measure them
• Discuss the performance of high fidelity Cas9 nucleases to further minimize the risk of off-target events.

Key Learning Objectives:

• Review the development process and quality controls of a GMP-manufactured Cas9 protein
• Describe the application of GMP-manufactured Cas9 in primary T-cell workflow
• Discuss causes of off-target events and how to minimize risk through high fidelity Cas9 and sgRNA selection

Who Should Attend:

• Biotech scientists, laboratory managers, R&D personnel, business development

Speakers

Jason Potter
R&D Director, Genome Editing
Thermo Fisher Scientific

Since graduating from Cornell, Jason Potter has spent 20 years working in biotech R&D. He has led research focusing on synthetic genes and the development of enzymes, including SuperScript III and other reverse transcriptases and polymerases, at Invitrogen /Life Technologies. He now leads the genome editing R&D team at Thermo Fisher Scientific in Carlsbad, Calif. His group is focused on developing and improving tools for genome editing using the TAL and CRISPR technologies.

Register Free: https://www.biopharminternational.com/bp_w/gmp

​